Trial Profile
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Navitoclax (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- 01 Aug 2023 Planned End Date changed from 30 Jul 2023 to 30 Jul 2024.
- 01 Aug 2023 Planned primary completion date changed from 30 Jul 2023 to 30 Jul 2024.
- 02 Aug 2022 Planned End Date changed from 30 Jul 2022 to 30 Jul 2023.